NCT01460706

Imaging Malignant Glioma With 68Ga-DOTATOC PET/CT

PET/CT Imaging of Malignant Glioma With Somatostatin Analog 68Ga-DOTATOC

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Turku University Hospital · Other Government
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to characterize tumour uptake of somatostatin analog 68Ga-DOTATOC in patients with either primary or recurrent malignant glioma. The investigators hypothesis is that some primary and recurrent malignant gliomas overexpress SST2 receptor which can be imaged with 68Ga-DOTATOC PET/CT. The investigators also hypothesize that tumor uptake of 68Ga-DOTATOC correlates with immunohistochemically determined SST2 receptor status of the tumor specimen.

Conditions

• Glioma

Interventions

Type	Name	Description
DRUG	[68Ga]DOTATOC	120MBq 68Ga-DOTATOC intravenously and PET/CT imaging. Performed once to a patient before the surgery.

Timeline

• Start date: 2011-10-01
• Primary completion: 2013-12-01
• Completion: 2013-12-01
• First posted: 2011-10-27
• Last updated: 2013-12-12

Locations

1 site across 1 country: Finland